Sergey Matveev

Sergey Matveev

Auto-generated profile, based on publicly available information

Sergey Matveev

Pirogov National Medical and Surgical Center

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Bulletin of Pirogov National Medical & Surgical Center
Verified
Journal Article
Closed access
AZA.B. Zemlyanoj
A.B. Zemlyanoj
AAA.G. Afinogenova
A.G. Afinogenova
SMS.A. Matveev
S.A. Matveev

1 January 2021 in Bulletin of Pirogov National Medical & Surgical Center
Verified
Journal Article
Closed access
PKP.E. Krainyukov
P.E. Krainyukov
ISI.A. Solovyov
I.A. Solovyov
SMS.A. Matveev
S.A. Matveev
VKV.V. Kokorin
V.V. Kokorin
RSR.P. Susov
R.P. Susov

28 December 2019 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
IPIgor Plaksa
Igor Plaksa
NMNina Mzhavanadze
Nina Mzhavanadze
RKRoman E. Kalinin
Roman E. Kalinin
ISIgor Suchkov
Igor Suchkov
MBMichail Bakunov
Michail Bakunov
RDRoman Deev
Roman Deev
BACKGROUND: The syndrome of diabetic foot remains the main cause of non-traumatic amputation of the lower extremity in the world. Even with the provision of comprehensive medical care in the conditions of a specialized center, 10-15% of patients do not succeed in healing the ulcerative defect due to the ischemic component. AIMS: The objective of this study is evaluation of safety and efficacy of pl-VEGF165 transfer in patients with neuroischemic type of diabetic foot syndrome. METHODS: The pilot study included 35 diabetic patients with neuroischemic foot ulcers (Wagner stage 1-2) who were not candidates for revascularization procedures (NCT02538705). The patients were closely monitored after repeated pl-VEGF165 intramuscular gene transfer (2,4 mg) at 1, 3, and 6 months after treatment. The primary efficacy endpoint was the surface area of the ulcers (sq.cm), the secondary endpoints were transcutaneous oxygen tension (Tcp02), ankle-brachial index (ABI), neuropathy disability score (NDS), neuropathy symptoms score (NSS), and Michigan neuropathy screening instrument (MNSI). Adverse events were monitored throughout the study. RESULTS: The use of pl-VEGF165 as part of complex treatment allowed to achieve wound healing in 65,7% of patients with chronic ulcerative defects, the safety of the target limb was 84%. Carrying out therapeutic angiogenesis as a part of the combined therapy ensured a reduction in the average area of the resistant to treatment defects from 3.6 [1.0; 7.05] cm2 to 0.0 [0.0;2.0] cm2 (p=0,001), which correlated with an increase in the TcPo2 index by 15% from 35 [29.5; 40.5] to 40.5 [36.0; 46.5] mm Hg (p= p=0,005) and in the ABI by 16% from 0.96 [0.82;1.08] to 1.11 [0.85; 1.24] (p=0,062). The decrease in the signs of diabetic neuropathy was determined - the scores of NSS scales and VAT decreased from 6,5 [5.75; 8.0) to 6.0 [5.25; 7.0] (p=0,004) and from 9.0 [8.0; 13.5] to 8.0 [7.0; 12.7] (p=0,001), respectively. No adverse effects associated with the use of pl-VEGF165 were recorded. CONCLUSIONS: Thus, preliminary results of the pilot study show that the use of pl-VEGF165 gene transfer in combination therapy allows for complete healing of neuroischemic diabetic foot ulcers in the majority of patients.

1 January 1996
Verified
Journal Article
Closed access
ISIu L Shevchenko
Iu L Shevchenko
VGV A Grishanin
V A Grishanin
SMS A Matveev
S A Matveev
KMK V Mazaĭshvili
K V Mazaĭshvili


1 January 2001
Verified
Journal Article
Closed access
VKV I Kuvakin
V I Kuvakin
VLV S Linnik
V S Linnik
NSN A Sokolovskiĭ
N A Sokolovskiĭ
SMS A Matveev
S A Matveev